Persistence with treatment in newly treated middle-aged patients with essential hypertension

Annals of Pharmacotherapy

Volumn 39, Issue 9, 2005, Pages 1401-1408

  Perreault, Sylvie ^a   Lamarre, Diane ^a   Blais, Lucie ^a   Dragomir, Alice ^a   Berbiche, Djamal ^a   Lalonde, Lyne ^a   Laurier, Claudine ^a   St Maurice, François ^a   Collin, Johanne ^a  

^a UNIVERSITÉ DE MONTRÉAL   (Canada)

Author keywords

Antihypertensive agents: determinants; Hypertension; Persistence

Indexed keywords

ANGIOTENSIN RECEPTOR ANTAGONIST; ANTIHYPERTENSIVE AGENT; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CALCIUM CHANNEL BLOCKING AGENT; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; DIURETIC AGENT;

ADULT; ARTICLE; CARDIOVASCULAR DISEASE; COMBINATION CHEMOTHERAPY; CONTROLLED STUDY; DATA BASE; DIABETES MELLITUS; DISEASE ASSOCIATION; DIURESIS; DYSLIPIDEMIA; ESSENTIAL HYPERTENSION; EVALUATION; FEMALE; FOLLOW UP; HUMAN; KAPLAN MEIER METHOD; MAJOR CLINICAL STUDY; MALE; MORBIDITY; MORTALITY; PRESCRIPTION; PRIORITY JOURNAL; TREATMENT OUTCOME;

AGE FACTORS; ANTIHYPERTENSIVE AGENTS; CARDIOVASCULAR DISEASES; COHORT STUDIES; DATABASES, FACTUAL; DIABETES COMPLICATIONS; DIURETICS; FEMALE; HUMANS; HYPERLIPIDEMIAS; HYPERTENSION; MALE; MIDDLE AGED; PATIENT COMPLIANCE; QUEBEC; REGRESSION ANALYSIS; RISK FACTORS; SURVIVAL ANALYSIS;

EID: 23944499073     PISSN: 10600280     EISSN: None     Source Type: Journal    
DOI: 10.1345/aph.1E548     Document Type: Article

References (55)

1. Joffres MR, Hamet P, Rabkin SW, Gelskey D, Hogan K, Fodor G. Prevalence, control and awareness of high blood pressure among Canadian adults. Canadian Heart Health Surveys Research Group. CMAJ 1992;146:1997-2005.
2. Alderman MH, Furberg CD, Kostis JB, Laragh JH, Psaty BM, Ruilope LM, et al. Hypertension guidelines: criteria that might make them more clinically useful. Am J Hypertens 2002;15:917-23.
3. Hansson L, Lindholm LH, Niskanen L, Lanke J, Hedner T, Niklason A, et al. Effect of angiotensin-converting-enzyme inhibition compared with conventional therapy on cardiovascular morbidity and mortality in hypertension: the Captopril Prevention Project (CAPPP) randomised trial. Lancet 1999;353:611-6.
4. Hansson L, Lindholm L, Ekbom T, Dahlöf B, Lanke J, Schersten B, et al. Randomised trial of old and new antihypertensive drugs in elderly patients: cardiovascular mortality and morbidity the Swedish Trial in Old Patients with Hypertension-2 study. Lancet 1999;354:1751-6.
5. UK Prospective Diabetes Study Group. Efficacy of atenolol and captopril in reducing risk of macrovascular and microvascular complication in type 2 diabetes: UKPDS 39. BMJ 1998;317:713-20.
6. UK Prospective Diabetes Study Group. Tight blood pressure control and risk of macrovascular and microvascular complications in type 2 diabetes: UKPDS 38. BMJ 1998;317:703-13.
7. Brown MJ, Palmer CR, Castaigne A, de Leeuw PW, Mancia G, Rosenthal T, et al. Morbidity and mortality in patients randomised to double-blind treatment with a long-acting calcium-channel blocker or diuretic in the International Nifedipine GITS study: Intervention as a Goal in Hypertension Treatment (INSIGHT). Lancet 2000;356:366-72.
8. National Intervention Cooperative Study in Elderly Hypertension Study group. Randomized double-blind comparison of a calcium antagonist and a diuretic in elderly hypertensives. Hypertension 1999;34:1129-33.
9. Hansson L, Hedner T, Lund-Johansen P, Kjeldsen SE, Lindholm LH, Syvertsen JO, et al., for the NORDIL Study Group. Randomised trial of effects of calcium antagonists compared with diuretics and β-blockers on cardiovascular morbidity and mortality in hypertension: the Nordic Dilti-azem (NORDIL) study. Lancet 2000;356:359-65.
10. Agabiti-Rosei E, Dal Palu C, Leonetti G, Magnani B, Pessina A, Zanchetti A. Clinical results of the Verapamil in Hypertension and Atherosclerosis Study. J Hypertens 1997;15:1337-44.
11. Zanchetti A, Agabiti-Rosei E, Dal Palu C, Leonetti G, Magnani B, Pessina A. The Verapamil in Hypertension and Atherosclerosis Study (VHAS): results of long-term randomised treatment with either Verapamil or chlorthalidone on intima-media thickness. J Hypertens 2000;16:1667-76.
12. Estacio R, Jeffers B, Hiatt W, Biggerstaff SL, Gifford N, Schrier RW. The effect of nisoldipine as compared to enalapril on cardiovascular outcomes in patients with non-insulin dependent diabetes and hypertension. N Engl J Med 1998;338:645-52.
13. Black HR, Elliott WJ, Grandits G, Neaton JD, Grimm RH Jr, Hansson L, et al. Principal results of the controlled onset Verapamil investigation of cardiovascular end points (CONVINCE) trial. JAMA 2003;289:2073-82.
14. Dahlöf B, Devereux RB, Kjeldsen SE, Julius S, Beevers G, de Fake U, et al. Cardiovascular morbidity and mortality in the Losartan Intervention for End Point Reduction in Hypertension study (LIFE): a randomized trial against atenolol. Lancet 2002;359:995-1003.
15. Blood Pressure Lowering Treatment Trialists' Collaboration. Effects of ACE inhibitors, calcium antagonists, and other blood-pressure-lowering drugs: results of prospectively designed overviews of randomized trials. Lancet 2000;355:1955-64.
16. The ALLHAT Officers and Coordinators for the ALLHAT Collaborative Research Group. Major outcomes in high-risk hypertensive patients randomized to angiotensin-converting enzyme inhibitor or calcium channel blocker vs. diuretics. The Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT). JAMA 2002;288:2981-97.
17. Wing LMH, Reid CM, Ryan P, Beilin LJ, Brown MA, Jennings GL, et al. A comparison of outcomes with angiotensin-converting-enzyme inhibitors and diuretics for hypertension in the elderly. N Engl J Med 2003;348:583-92.
18. Psaty BM, Lumley T, Furberg CD, Schellenbaum G, Pahor M, Alderman MH, et al. Health outcomes associated with various antihypertensive therapies used as first-line agents. JAMA 2003;289:2534-44.
19. Blood Pressure Lowering Treatment Trialists Collaboration. Effects of different blood-pressure lowering regimens on major cardiovascular disease events: results of prospectively-designed overviews of randomized trials. Lancet 2003;362:1527-35.
20. Du X, Cruickshank K, McNamee R, Sarall M, Sourbutts J, Summers A, et al. Case-control study of stroke and the quality of hypertension control in North West England. BMJ 1997;314:272-6.
21. Joffres MR, Ghadirian P, Fodor JG, Petrasovits A, Chockalingam A, Harnet P. Awareness, treatment, and control of hypertension in Canada. Am J Hypertens 1997;10:1097-102.
22. Perreault S, Dorais M, Coupal L, Paradis G, Joffres MR, Graver SA. Impact of treating hyperlipidemia or hypertension to reduce the risk of death from coronary artery disease. CMAJ 1999;160:1449-55.
23. Hajjar I, Kotchen TA. Trends in prevalence, awareness, treatment and control of hypertension in the United States, 1988-2000. JAMA 2003; 290:199-206.
24. Wolf-Maier K, Cooper RS, Banegas JR, Giampaoli S, Hense HW, Joffres M, et al. Hypertension prevalence and blood pressure levels in 6 European countries, Canada, and the United States. JAMA 2003;289:2363-9.
25. Mancia G, Sega R, Milesi C, Cesana G, Zanchetti A. Blood pressure control in the hypertensive population. Lancet 1999;349:454-7.
26. Bittar N. Maintaining long-term control of blood pressure: the role of improved compliance. Clin Cardiol 1995;18:312-6.
27. Jones JK, Gorkin L, Lian JF, Staffa JA, Fletcher AP. Discontinuation of and changes in treatment after start of new courses of antihypertensive drugs: a study of a United Kingdom population. BMJ 1995;311:293-5.
28. Hamilton RA, Briceland LL. Use of prescription-refill records to assess patient compliance. Am J Hosp Pharm 1992;49:1691-9.
29. Elliott WJ. Discontinuation rates for ACE inhibitors and calcium antagonists in a tertiary hypertension clinic (abstract). Am J Hypertens 1993;6: 94A.
30. Shea S, Misra D, Ehrlich MG, Field L, Francis CK. Correlates of nonadherence to hypertension treatment in an inner-city minority population. Am J Public Health 1992;82:1607-12.
31. Sharkness CM, Snow DA. The patient's view of hypertension and compliance. Am J Prev Med 1992;8:141-6.
32. Cooper JK, Love DW, Raffoul PR. Intentional prescription nonadherence (noncompliance) by the elderly. J Am Geriatr Soc 1982;30:329-33.
33. Monane M, Bohn RL, Gurwitz JH, Glynn RJ, Levin R, Avorn J. The effects of initial drug choice and co-morbidity on antihypertensive therapy compliance: results from a population-based study in the elderly. Am J Hypertens 1997;10:697-704.
34. Okano GL, Rascati KL, Wilson JP, Remund DD, Grabenstein JD, Brixner DL. Patterns of antihypertensive use among patients in the US Department of Defense database initially prescribed an angiotensin-converting enzyme inhibitor or calcium channel blocker. Clin Ther 1997;19: 1433-45.
35. Caro JJ, Salas M, Speckman JL, Raggio G, Jackson JD. Persistence with treatment for hypertension in actual practice. CMAJ 1999;160:31-7.
36. Caro JJ, Speckman JL, Salas M, Raggio G, Jackson JD. Effect of initial drug choice on persistence with antihypertensive therapy: the importance of actual practice data. CMAJ 1999;160:41-6.
37. World Health Organization. International classification of diseases. Manual of the international statistical classification of diseases, injuries, and cause of death. 9th revision. No. PHS 80-1260. Geneva: World Health Organization, 1977.
38. Statistics Canada Health Division. Canadian classification of diagnostic, therapeutic and surgical procedures. 2nd ed. Ottawa: Supply and Services, 1986.
39. Régie de l'assurance maladie du Québec. Ministry of Health, Government of Québec, Québec: Régie de l'assurance maladie du Québec, 1997.
40. Moride Y, Abenhaim L. The depletion of susceptible effects in non-experimental pharmacoepidemiologic research. J Clin Epidemiol 1994;47: 731-7.
41. Tamblyn R, Lavoie G, Petrella L, Monette J. The use of prescription claims databases in pharmacoepidemiological research: the accuracy and comprehensiveness of the prescription claims database in Quebec. J Clin Epidemiol 1995;48:999-1009.
42. Wang PS, Bohn RL, Knight E, Glynn RJ, Mogun H, Avorn J. Noncompliance with antihypertensive medications: the impact of depressive symptoms and psychosocial factors. J Gen Intern Med 2002;17:504-11.
43. Di Matteo MR, Lepper HS, Croghan TW. Depression is a risk factor for noncompliance with medical treatment: meta-analysis of the effect of anxiety and depression on patient adherence. Arch Intern Med 2000; 160:2101-7.
44. Kalbfleisch JP, Prentice RL, eds. The statistical analysis of failure time data. New York: John Wiley & Sons, 1980.
45. Rosner B. Hypothesis testing: categorical data. In: Fundamentals of biostatistics. Boston: PWS Publishers, 1986:302-67.
46. Greene WH. Econometric analysis. 3rd ed. Upper Saddle River, NJ: Prentice-Hall, 1997:552.
47. Belsley DA, Kuy E, Welsch RE. Regression diagnostics: identifying influential data and sources of collinearity. New York: John Wiley & Sons, 1981.
48. Psaty BM, Smith NL, Siscovick DS, Koepsell TD, Weiss NS, Heckbert SR, et al. Health outcomes associated with antihypertensive therapies used as first-line agents. A systematic review and meta-analysis. JAMA 1997;277:739-45.
49. Bloom BS. Continuation of initial antihypertensive medication after 1 year of therapy. Clin Ther 1998;2:671-81.
50. Chaput AJ. Persistence with angiotensin receptor blockers (ARB) versus other antihypertensives (AHT) using the Saskatchewan database. Can J Cardiol 2000;16(suppl):194A.
51. Hasford J, Mimran A, Simons WR. A population-based European cohort study of persistence in newly diagnosed hypertensive patients. J Human Hyper 2002;16:569-75.
52. Benson S, Vance-Bryuan K, Radatz J. Time to patient discontinuation of antihypertensive drugs in different classes. Am J Health Syst Pharm 2000;57:51-4.
53. Cohen JS. Adverse drug effects, compliance and initial doses of antihypertensive drugs recommended by the Joint National Committee vs. the Physicians' Desk Reference. Arch Intern Med 2001;161:880-5.
54. Grégoire JP, Moisan J, Guibert R, Ciampi A, Milot A, Gaudet M, et al. Determinants of discontinuation of new courses of antihypertensive medications. J Clin Epidemiol 2002;55:728-35.
55. McDonald HP, Garg AX, Haynes RB. Interventions to enhance patient adherence to medication prescriptions. JAMA 2002;288:2868-79